Merck & Co. focuses on oncology and vaccines as investors watch long-term growth

By Thomas Clarke, Operations & Strategy desk. Reviewed on July 6, 2026 at 4:27 p.m. ET.

Merck & Co. (ISIN US58933Y1055) is one of the largest global pharmaceutical companies and a long-standing member of major US equity benchmarks such as the S&P 500, reflecting its scale and relevance for US investors.

Oncology and vaccine engine

Merck & Co., Inc. generates a significant share of its revenue from oncology medicines, with a flagship immune-oncology therapy that is widely used across multiple cancer indications worldwide. The company has steadily expanded approved uses for this therapy over the years, aiming to deepen its presence in lung, melanoma, and other solid-tumor segments.

In addition to cancer, Merck has a meaningful portfolio of vaccines that target infectious diseases across age groups, including pediatric, adolescent, and adult populations. These vaccines contribute recurring revenue and help balance the cyclical nature of some therapeutic areas, making the vaccine business a strategic pillar for long-term cash flow.

Research pipeline and strategy

Merck invests heavily in research and development, with annual R&D spending in the order of billions of US dollars to advance new medicines in oncology, vaccines, cardiometabolic conditions, and other specialty areas. The company’s strategy emphasizes both internal discovery and external collaboration, including licensing agreements and partnerships that can bring in promising assets from smaller biotech firms.

Analysts who follow large-cap pharmaceuticals often highlight that patent life cycles and competition from generics and biosimilars can significantly influence future earnings. Against this backdrop, Merck’s pipeline of late-stage clinical programs, together with lifecycle management for existing brands, plays a central role in supporting its long-term growth narrative.

Key oncology product

Merck’s leading oncology product is an immune checkpoint inhibitor designed to help the body’s own immune system recognize and attack cancer cells. It is administered primarily by infusion and has become a cornerstone therapy in multiple tumor types, often used alone or in combination with chemotherapy or other targeted treatments.

The medicine’s broad label in major markets, including the United States, Europe, and parts of Asia, means that its performance is closely watched by healthcare professionals and investors alike. For Merck, continued clinical data, label expansions, and geographic growth are all important drivers that can sustain revenue from this therapy as competitors bring alternative options to market.

Merck stock and market view

Merck & Co. trades on the New York Stock Exchange in US dollars, reflecting its status as a US-based blue-chip healthcare company. As a large component of healthcare-focused portfolios and index funds, the stock can be influenced by sentiment on drug pricing policy, healthcare utilization trends, and broader risk appetite in global equity markets.

For long-term investors, Merck’s combination of established franchises, a deep research pipeline, and exposure to defensive healthcare demand is often seen as a key part of its investment case, even though individual price moves depend on market conditions, earnings results, and regulatory decisions that can change over time.

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.